DNA Sequencing Market Trends (Kalorama Survey of Lab Using Next-Gen and Capillary Systems)
ProdUnitPrice (Single User PDF): $3,995.00
ProdUnit Price (Global Site License): $7,990.00
How are labs using DNA sequencing technology today? How many and what type of systems are installed? What applications are seeing the most usage? Have second and third generation systems penetrated as expected? What systems to labs plan to purchase in the future and when?
Authored and conducted by Justin Saeks, Kalorama Information's senior biotech analyst and author of DNA Sequencing Markets report, this report attempts to answer these questions and more, taking a quantitative view of the sequencing marketplace. The survey encompasses next-gen and capillary systems, with an emphasis on trends in second and third generations. Academic,research, government and other labs were interviewed for this study.
The DNA sequencer market has undergone rapid changes in the last few years, unlike any period in its history and also unique relative to most technologies except the computer or the chip. The rapid ongoing technological advances have enabled a Moore’s Law type of phenomenon in relation to the cost of sequencing and the output of the systems.
Kalorama Information’s Next Generation Sequencing Survey of U.S. Research Labs aims to identify some of the key changes taking place with both next-generation systems and capillary sequencers in relation to their usage in labs.
This market study includes:
ProdUnit Price (Global Site License): $7,990.00
How are labs using DNA sequencing technology today? How many and what type of systems are installed? What applications are seeing the most usage? Have second and third generation systems penetrated as expected? What systems to labs plan to purchase in the future and when?
Authored and conducted by Justin Saeks, Kalorama Information's senior biotech analyst and author of DNA Sequencing Markets report, this report attempts to answer these questions and more, taking a quantitative view of the sequencing marketplace. The survey encompasses next-gen and capillary systems, with an emphasis on trends in second and third generations. Academic,research, government and other labs were interviewed for this study.
The DNA sequencer market has undergone rapid changes in the last few years, unlike any period in its history and also unique relative to most technologies except the computer or the chip. The rapid ongoing technological advances have enabled a Moore’s Law type of phenomenon in relation to the cost of sequencing and the output of the systems.
Kalorama Information’s Next Generation Sequencing Survey of U.S. Research Labs aims to identify some of the key changes taking place with both next-generation systems and capillary sequencers in relation to their usage in labs.
This market study includes:
- Status of Next Gen and Third Gen Systems
- Future Purchasing Plans and Time Frame
- Run Frequencies
- Sequencing Applications
- Features Liked and Disliked by Brand (454, ABI SOLID, Illumina)
- U.S. vs. Europe and Rest of World Stats
- Over 105 Exhibits to Illuminate Survey
- Main Challenges/Bottlenecks to Usage
- Difficulty of Data Analysis by Brand/Type
- Difficulty of Data Managment by Brand/Type
- Sequencing Models Respondents Are Likely to Consider
- Verbatim Comments of Respondents
- Analyst Conclusions
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope
Methodology
Outline
Demographics
Major Conclusions
CHAPTER TWO: DEMOGRAPHICS
Demographics
Industrial Distribution of Respondents’ Labs
Laboratory Function of Respondents’ Labs
Distribution by Number of Sequencers
Total Numbers of Systems in Labs
Numbers of 2nd and 3rd Generation Systems
Numbers of Capillary/ Gel Systems
Number of Sequencers in Other Labs
Brand(s)/ Types(s) of Sequencers Owned, Overall
Types of Sample Being Studied
Position/ Role of Respondents
CHAPTER THREE: SYSTEM INSTALLATIONS
Overall Installed Base
Distribution of Sequencer Models
Overall Totals
Versions of 2nd-Generation Systems
Installed Base by Next-Gen vs Capillary: System Owned
Distribution of Number of Sequencers
Installed Base by Region
Overall Brand/ Type
Next-Generation Systems
Capillary / Gel Systems
Installed Base by Industry Segment
Overall Brand/ Type
Next-Generation Systems
Capillary / Gel Systems
Installed Base by Laboratory Function
Overall Brand/ Type
Next-Generation Systems
System Prices
Date of Installation
Distribution by Next-Generation vs Capillary
CHAPTER FOUR: APPLICATIONS AND USAGE TRENDS
Frequency of Sequencer Runs
Next-Generation Systems
Capillary Systems
Outsourcing
Output, Read Lengths, Single- or Paired-Ends
Next-Generation Systems
Capillary Systems
Targeted Enrichment Systems Being Used
CHAPTER FIVE: PREFERENCES AND EVALUATIONS
CHAPTER SIX: FUTURE PURCHASE PLANS
Introduction
Scope
Methodology
Outline
Demographics
Major Conclusions
CHAPTER TWO: DEMOGRAPHICS
Demographics
Industrial Distribution of Respondents’ Labs
Laboratory Function of Respondents’ Labs
Distribution by Number of Sequencers
Total Numbers of Systems in Labs
Numbers of 2nd and 3rd Generation Systems
Numbers of Capillary/ Gel Systems
Number of Sequencers in Other Labs
Brand(s)/ Types(s) of Sequencers Owned, Overall
Types of Sample Being Studied
Position/ Role of Respondents
CHAPTER THREE: SYSTEM INSTALLATIONS
Overall Installed Base
Distribution of Sequencer Models
Overall Totals
Versions of 2nd-Generation Systems
Installed Base by Next-Gen vs Capillary: System Owned
Distribution of Number of Sequencers
Installed Base by Region
Overall Brand/ Type
Next-Generation Systems
Capillary / Gel Systems
Installed Base by Industry Segment
Overall Brand/ Type
Next-Generation Systems
Capillary / Gel Systems
Installed Base by Laboratory Function
Overall Brand/ Type
Next-Generation Systems
System Prices
Date of Installation
Distribution by Next-Generation vs Capillary
CHAPTER FOUR: APPLICATIONS AND USAGE TRENDS
Frequency of Sequencer Runs
Next-Generation Systems
Capillary Systems
Outsourcing
Output, Read Lengths, Single- or Paired-Ends
Next-Generation Systems
Capillary Systems
Targeted Enrichment Systems Being Used
CHAPTER FIVE: PREFERENCES AND EVALUATIONS
CHAPTER SIX: FUTURE PURCHASE PLANS
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Exhibit ES-1: Distribution of Survey Respondent Labs, by Type
CHAPTER TWO: DEMOGRAPHICS
Exhibit 1: Regional Distribution of Labs (North America, Europe, Asia-Pacific, R.O.W)
Exhibit 2: Industrial Distribution of Labs (Academia, Hospital, Indep. Research/Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 3: Industrial Distribution of Labs, by Region (# of Labs)
Exhibit 4: Industrial Distribution of Labs, Cross-Referenced by Region (% of Labs)
Exhibit 5: Major Function(s) of Labs (Core Lab, Service Provider, Research, Genome Center, Diagnostics, Teaching, Bioinformatics, Overall)
Exhibit 6: Major Function(s) of Labs, by Region (# of Labs)
Exhibit 7: Major Function(s) of Labs, Cross Referenced by Region (% of Labs)
Exhibit 8: Distribution of Total Number of Sequencers in Respondent Labs
Exhibit 9: Distribution of Number of Next-Generation Sequencers in Labs
Exhibit 10: Distribution of Number of Capillary/ Gel Sequencers in Labs
Exhibit 11: Distribution of Number of Sequencers Elsewhere in Organization
Exhibit 12: Brands/ Types of Sequencers Owned Overall in Respondent Labs(Next gen, ABI/Life Tech., ABI Capillary/ Gel, Illumina, 454, ABI SOLiD, No sequencer)
Exhibit 13: Average Number of Sequencers in Respondent Labs, by Brand/ Type
Exhibit 14: Main Types of Samples Being Sequenced in Labs (Human, Bacteria, Plant, Agricultural, Animals, Variety, Other)
Exhibit 15: Distribution of Positions/ Roles of Respondents
CHAPTER THREE: SYSTEM INSTALLATIONS
Exhibit 16: Installed Base of Respondent Labs, by Model
Exhibit 17: Distribution of ABI SOLiD System Versions in Respondents’ Labs
Exhibit 18: Installed Base of Models in Labs, by Brand/ Type of System(s) Owned (# of Systems)
Exhibit 19: Installed Base of Models in Labs, Cross-Referenced by Brand/ Type of System(s) Owned (% of Systems)
Exhibit 20: Installed Base of Labs by Brand/ Type of System Owned, Cross-Referenced by Model (% of Systems)
Exhibit 21: Distribution of Number of Sequencers, by Number of Next-Generation Systems vs Number of Capillary Systems (# of Labs)
Exhibit 22: Distribution of Number of Sequencers, by Number of Next-Generation Systems vs Number of Capillary Systems (% of Labs)
Exhibit 23: Distribution of Number of Sequencers, by Number of Capillary Systems vs Number of Next-Generation Systems (% of Labs)
Exhibit 24: Average Number of Systems Installed in Respondent Labs, by Region (N. America, Europe, Asia, R.O.W.)
Exhibit 25: Sequencer Models in Respondent Labs, by Region (# of Systems)
Exhibit 26: Sequencer Models in Respondent Labs, by Region (% of Systems)
Exhibit 27: Next-Gen Sequencer Models in Respondent Labs, by Region (# of Systems)
Exhibit 28: Next-Gen Sequencer Models in Respondent Labs, by Region (% of Systems)
Exhibit 29: Capillary and Gel Sequencer Models in Labs, by Region (# of Systems)
Exhibit 30: Capillary and Gel Sequencer Models in Labs, by Region (% of Systems)
Exhibit 31: Average Number of Sequencers Installed by Industry/ Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Research/ Svcs, Government, Other)
Exhibit 32: Industrial Distribution of Systems, by Brand/ Type (# of Systems)
Exhibit 33: Industrial Distribution of Systems, by Brand/ Type (% of Systems)
Exhibit 34: Brand/ Type of Sequencer System Installed, Cross-Referenced by Industry/ Segment (% of Systems)
Exhibit 35: Number of Next-Generation Systems in Labs Owning, by Industry/Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 36: Industrial Distribution of Next-Generation Sequencers, by Model (# of Systems)
Exhibit 37: Industrial Distribution of Next-Generation Sequencers, by Model (% of Systems)
Exhibit 38: Next-Generation Models in Respondent Labs, by Industry/ Segment (% of Systems)
Exhibit 39: Capillary/Gel Systems Installed in Lab Owning, by Industry/Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 40: Industrial Distribution of Capillary/Gel Sequencers, by Model (# of Systems)
Exhibit 41: Industrial Distribution of Capillary/Gel Sequencers, by Model (% of Systems)
Exhibit 42: Capillary/ Gel Sequencer Models in Labs, by Industry/ Segment (% of Systems)
Exhibit 43: Average Number of Systems Installed by Laboratory Function
Exhibit 44: Distribution of Systems by Lab Function, by Brand/ Type (# of Systems)
Exhibit 45: Distribution of Systems by Lab Function, by Brand/ Type (% of Systems)
Exhibit 46: Brand/Type of System Installed, Cross-Referenced by Lab Function (% of Systems)
Exhibit 47: Average Number of Next-Generation Systems in Labs Owning, by Lab Function
Exhibit 48: Next Generation Models in Respondent’s Labs, by Lab Function (# of Systems)
Exhibit 49: Distribution of Next-Generation Systems by Lab Function, Cross-Referenced by Model (% of Systems)
Exhibit 50: Next Generation Models in Respondent Labs, by Lab Function (% of Systems)
Exhibit 51: Average Number of Capillary/ Gel Systems in Labs Owning, By Lab Function
Exhibit 52: Distribution of Capillary/ Gel Sequencers by Lab Function, by Model (# of Systems)
Exhibit 53: Distribution of Capillary/ Gel Sequencers by Lab Function, by Model (% of Systems)
Exhibit 54: Capillary/ Gel Sequencer Models in Labs, by Lab Function (% of Systems)
Exhibit 55: Age of Next-Generation and Capillary Systems Installed in Labs, Q1 2000 - Q4 2004
Exhibit 56: Age of Next-Generation and Capillary Systems Installed in Labs, Q1 2005 - Q3 2010
Exhibit 57: Age of Next-Generation Systems in Respondent Labs by Model, Q3 2005 - Q3 2010
CHAPTER FOUR: APPLICATIONS AND USAGE TRENDS
Exhibit 58: Distribution of Runs/ Libraries by Application, by Brand/ Type (% of Samples)
Exhibit 59: Applications Expected to Increase the Most
Exhibit 60: Applications Expected to Increase the Most, for Next-Generation Systems
Exhibit 61: Applications Expected to Increase the Most, Capillary/Gel System Owners
Exhibit 62: Applications Expected to Increase the Most, by Brand/ Type Owned (# of Labs)
Exhibit 63: Applications Expected to Increase the Most, by Brand/ Type Owned (% of Labs)
Exhibit 64: Frequency that Next-Generation Systems are Running (# of Systems)
Exhibit 65: Frequency that Next-Generation Systems are Running (% of Systems)
Exhibit 66: Distribution of Number of Plates Run per Week, for Capillary Systems
Exhibit 67: Overall Distribution of Outsourcing of Sequencing
Exhibit 68: Regional Distribution of Outsourcing of Sequencing (# of Labs)
Exhibit 69: Regional Distribution of Outsourcing of Sequencing (% of Labs)
Exhibit 70: Distribution of Reasons for Outsourcing of Sequencing
Exhibit 71: Distribution of Typical Read Lengths of Capillary Systems
Exhibit 72: Distribution of Targeted Enrichment Systems Used by Labs
Exhibit 73: Distribution of Systems Used to Check Concentration, Size, Quality
CHAPTER FIVE: PREFERENCES AND EVALUATIONS
Exhibit 74: Labs’ Most Important Criteria for Sequencer Purchase
Exhibit 75: Labs’ Most Important Criteria for Sequencer Purchase, by Brand/ Type Owned (# of Labs)
Exhibit 76: Labs’ Most Important Criteria for Sequencer Purchase, by Brand/ Type Owned (% of Labs)
Exhibit 77: Labs’ Satisfaction Ratings of System Features by Brand/ Type (1-very dissatisf., 2-somewhat dissatisf., 3-avg. or indifferent, 4-slightly satisf., 5-very satisf.)
Exhibit 78: Satisfaction Ratings of Next-Generation System Features by Brand (1-very dissatisf., 2-somewhat dissatisf., 3-avg. or indifferent, 4-slightly satisf., 5-very satisf.)
Exhibit 79: Feature or Process Most Wanted to Change or Improve, by Brand/ Type (# of Labs)
Exhibit 80: Feature(s) or Process Most Wanted to Change or Improve, by Brand/Type (% of Labs)
Exhibit 81: Main Bottleneck(s) in Sequencing Process (# of Labs)
Exhibit 82: Main Bottleneck(s) in Sequencing Process (% of Labs)
Exhibit 83: Difficulty of Data Analysis, by Brand/ Type (# of Labs)
Exhibit 84: Difficulty of Data Analysis, by Brand/ Type (% of Labs)
Exhibit 85: Difficulty of Data Management, by Brand/ Type (# of Labs)
Exhibit 86: Difficulty of Data Management, by Brand/ Type (% of Labs)
CHAPTER SIX: FUTURE PURCHASE PLANS
Exhibit 87: Time Frame for Sequencer Purchase Plan(s)
Exhibit 88:Time Frame(s) for Sequencer Purchase Plan(s) (# and % of Systems)
Exhibit 89: Time Frame(s) for Sequencer Purchase Plan(s), by Brand/ Type Owned (# of Systems)
Exhibit 90: Time Frame(s) for Sequencer Purchase Plan(s), by Brand/ Type Owned (% of Systems)
Exhibit 91: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (# of Systems)
Exhibit 92: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (% of Systems)
Exhibit 93: Time Frame(s) for Sequencer Purchase Plan(s), by Lab Function (# of Systems)
Exhibit 94: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (% of Systems)
Exhibit 95: Time Frame(s) for Sequencer Purchase Plan(s), by Region (# of Systems)
Exhibit 96: Time Frame(s) for Sequencer Purchase Plan(s), by Region (% of Systems)
Exhibit 97: Sequencer Models Likely to Consider for Future Purchase
Exhibit 98: Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
Exhibit 99: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
Exhibit 100: Sequencer Models Likely to Consider, Capillary/ Gel System-Only Owners
Exhibit 101: Sequencer Models Likely to Consider, Next-Generation System-Only Owners
Exhibit 102: Sequencer Models Likely to Consider, by Industry/ Segment (# of Labs)
Exhibit 103: Sequencer Models Likely to Consider, by Industry/ Segment (% of Labs)
Exhibit 104: Sequencer Models Likely to Consider, by Lab Function (# of Labs)
Exhibit 105: Sequencer Models Likely to Consider, by Lab Function (% of Labs)
Exhibit 106: Sequencer Models Likely to Consider, by Region (# of Labs)
Exhibit 107: Sequencer Models Likely to Consider, by Region (% of Labs)
Exhibit 108: Barriers or Issues Hindering 2nd and 3rd Generation Sequencers (# of Labs)
Exhibit 109: Barriers or Issues Hindering 2nd and 3rd Generation Sequencers (% of Labs)
CHAPTER ONE: EXECUTIVE SUMMARY
Exhibit ES-1: Distribution of Survey Respondent Labs, by Type
CHAPTER TWO: DEMOGRAPHICS
Exhibit 1: Regional Distribution of Labs (North America, Europe, Asia-Pacific, R.O.W)
Exhibit 2: Industrial Distribution of Labs (Academia, Hospital, Indep. Research/Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 3: Industrial Distribution of Labs, by Region (# of Labs)
Exhibit 4: Industrial Distribution of Labs, Cross-Referenced by Region (% of Labs)
Exhibit 5: Major Function(s) of Labs (Core Lab, Service Provider, Research, Genome Center, Diagnostics, Teaching, Bioinformatics, Overall)
Exhibit 6: Major Function(s) of Labs, by Region (# of Labs)
Exhibit 7: Major Function(s) of Labs, Cross Referenced by Region (% of Labs)
Exhibit 8: Distribution of Total Number of Sequencers in Respondent Labs
Exhibit 9: Distribution of Number of Next-Generation Sequencers in Labs
Exhibit 10: Distribution of Number of Capillary/ Gel Sequencers in Labs
Exhibit 11: Distribution of Number of Sequencers Elsewhere in Organization
Exhibit 12: Brands/ Types of Sequencers Owned Overall in Respondent Labs(Next gen, ABI/Life Tech., ABI Capillary/ Gel, Illumina, 454, ABI SOLiD, No sequencer)
Exhibit 13: Average Number of Sequencers in Respondent Labs, by Brand/ Type
Exhibit 14: Main Types of Samples Being Sequenced in Labs (Human, Bacteria, Plant, Agricultural, Animals, Variety, Other)
Exhibit 15: Distribution of Positions/ Roles of Respondents
CHAPTER THREE: SYSTEM INSTALLATIONS
Exhibit 16: Installed Base of Respondent Labs, by Model
Exhibit 17: Distribution of ABI SOLiD System Versions in Respondents’ Labs
Exhibit 18: Installed Base of Models in Labs, by Brand/ Type of System(s) Owned (# of Systems)
Exhibit 19: Installed Base of Models in Labs, Cross-Referenced by Brand/ Type of System(s) Owned (% of Systems)
Exhibit 20: Installed Base of Labs by Brand/ Type of System Owned, Cross-Referenced by Model (% of Systems)
Exhibit 21: Distribution of Number of Sequencers, by Number of Next-Generation Systems vs Number of Capillary Systems (# of Labs)
Exhibit 22: Distribution of Number of Sequencers, by Number of Next-Generation Systems vs Number of Capillary Systems (% of Labs)
Exhibit 23: Distribution of Number of Sequencers, by Number of Capillary Systems vs Number of Next-Generation Systems (% of Labs)
Exhibit 24: Average Number of Systems Installed in Respondent Labs, by Region (N. America, Europe, Asia, R.O.W.)
Exhibit 25: Sequencer Models in Respondent Labs, by Region (# of Systems)
Exhibit 26: Sequencer Models in Respondent Labs, by Region (% of Systems)
Exhibit 27: Next-Gen Sequencer Models in Respondent Labs, by Region (# of Systems)
Exhibit 28: Next-Gen Sequencer Models in Respondent Labs, by Region (% of Systems)
Exhibit 29: Capillary and Gel Sequencer Models in Labs, by Region (# of Systems)
Exhibit 30: Capillary and Gel Sequencer Models in Labs, by Region (% of Systems)
Exhibit 31: Average Number of Sequencers Installed by Industry/ Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Research/ Svcs, Government, Other)
Exhibit 32: Industrial Distribution of Systems, by Brand/ Type (# of Systems)
Exhibit 33: Industrial Distribution of Systems, by Brand/ Type (% of Systems)
Exhibit 34: Brand/ Type of Sequencer System Installed, Cross-Referenced by Industry/ Segment (% of Systems)
Exhibit 35: Number of Next-Generation Systems in Labs Owning, by Industry/Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 36: Industrial Distribution of Next-Generation Sequencers, by Model (# of Systems)
Exhibit 37: Industrial Distribution of Next-Generation Sequencers, by Model (% of Systems)
Exhibit 38: Next-Generation Models in Respondent Labs, by Industry/ Segment (% of Systems)
Exhibit 39: Capillary/Gel Systems Installed in Lab Owning, by Industry/Segment (Academic, Hospital, Indep. Rsch/ Non-profit, Contract Rsch/ Svcs, Gov’t, Other)
Exhibit 40: Industrial Distribution of Capillary/Gel Sequencers, by Model (# of Systems)
Exhibit 41: Industrial Distribution of Capillary/Gel Sequencers, by Model (% of Systems)
Exhibit 42: Capillary/ Gel Sequencer Models in Labs, by Industry/ Segment (% of Systems)
Exhibit 43: Average Number of Systems Installed by Laboratory Function
Exhibit 44: Distribution of Systems by Lab Function, by Brand/ Type (# of Systems)
Exhibit 45: Distribution of Systems by Lab Function, by Brand/ Type (% of Systems)
Exhibit 46: Brand/Type of System Installed, Cross-Referenced by Lab Function (% of Systems)
Exhibit 47: Average Number of Next-Generation Systems in Labs Owning, by Lab Function
Exhibit 48: Next Generation Models in Respondent’s Labs, by Lab Function (# of Systems)
Exhibit 49: Distribution of Next-Generation Systems by Lab Function, Cross-Referenced by Model (% of Systems)
Exhibit 50: Next Generation Models in Respondent Labs, by Lab Function (% of Systems)
Exhibit 51: Average Number of Capillary/ Gel Systems in Labs Owning, By Lab Function
Exhibit 52: Distribution of Capillary/ Gel Sequencers by Lab Function, by Model (# of Systems)
Exhibit 53: Distribution of Capillary/ Gel Sequencers by Lab Function, by Model (% of Systems)
Exhibit 54: Capillary/ Gel Sequencer Models in Labs, by Lab Function (% of Systems)
Exhibit 55: Age of Next-Generation and Capillary Systems Installed in Labs, Q1 2000 - Q4 2004
Exhibit 56: Age of Next-Generation and Capillary Systems Installed in Labs, Q1 2005 - Q3 2010
Exhibit 57: Age of Next-Generation Systems in Respondent Labs by Model, Q3 2005 - Q3 2010
CHAPTER FOUR: APPLICATIONS AND USAGE TRENDS
Exhibit 58: Distribution of Runs/ Libraries by Application, by Brand/ Type (% of Samples)
Exhibit 59: Applications Expected to Increase the Most
Exhibit 60: Applications Expected to Increase the Most, for Next-Generation Systems
Exhibit 61: Applications Expected to Increase the Most, Capillary/Gel System Owners
Exhibit 62: Applications Expected to Increase the Most, by Brand/ Type Owned (# of Labs)
Exhibit 63: Applications Expected to Increase the Most, by Brand/ Type Owned (% of Labs)
Exhibit 64: Frequency that Next-Generation Systems are Running (# of Systems)
Exhibit 65: Frequency that Next-Generation Systems are Running (% of Systems)
Exhibit 66: Distribution of Number of Plates Run per Week, for Capillary Systems
Exhibit 67: Overall Distribution of Outsourcing of Sequencing
Exhibit 68: Regional Distribution of Outsourcing of Sequencing (# of Labs)
Exhibit 69: Regional Distribution of Outsourcing of Sequencing (% of Labs)
Exhibit 70: Distribution of Reasons for Outsourcing of Sequencing
Exhibit 71: Distribution of Typical Read Lengths of Capillary Systems
Exhibit 72: Distribution of Targeted Enrichment Systems Used by Labs
Exhibit 73: Distribution of Systems Used to Check Concentration, Size, Quality
CHAPTER FIVE: PREFERENCES AND EVALUATIONS
Exhibit 74: Labs’ Most Important Criteria for Sequencer Purchase
Exhibit 75: Labs’ Most Important Criteria for Sequencer Purchase, by Brand/ Type Owned (# of Labs)
Exhibit 76: Labs’ Most Important Criteria for Sequencer Purchase, by Brand/ Type Owned (% of Labs)
Exhibit 77: Labs’ Satisfaction Ratings of System Features by Brand/ Type (1-very dissatisf., 2-somewhat dissatisf., 3-avg. or indifferent, 4-slightly satisf., 5-very satisf.)
Exhibit 78: Satisfaction Ratings of Next-Generation System Features by Brand (1-very dissatisf., 2-somewhat dissatisf., 3-avg. or indifferent, 4-slightly satisf., 5-very satisf.)
Exhibit 79: Feature or Process Most Wanted to Change or Improve, by Brand/ Type (# of Labs)
Exhibit 80: Feature(s) or Process Most Wanted to Change or Improve, by Brand/Type (% of Labs)
Exhibit 81: Main Bottleneck(s) in Sequencing Process (# of Labs)
Exhibit 82: Main Bottleneck(s) in Sequencing Process (% of Labs)
Exhibit 83: Difficulty of Data Analysis, by Brand/ Type (# of Labs)
Exhibit 84: Difficulty of Data Analysis, by Brand/ Type (% of Labs)
Exhibit 85: Difficulty of Data Management, by Brand/ Type (# of Labs)
Exhibit 86: Difficulty of Data Management, by Brand/ Type (% of Labs)
CHAPTER SIX: FUTURE PURCHASE PLANS
Exhibit 87: Time Frame for Sequencer Purchase Plan(s)
Exhibit 88:Time Frame(s) for Sequencer Purchase Plan(s) (# and % of Systems)
Exhibit 89: Time Frame(s) for Sequencer Purchase Plan(s), by Brand/ Type Owned (# of Systems)
Exhibit 90: Time Frame(s) for Sequencer Purchase Plan(s), by Brand/ Type Owned (% of Systems)
Exhibit 91: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (# of Systems)
Exhibit 92: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (% of Systems)
Exhibit 93: Time Frame(s) for Sequencer Purchase Plan(s), by Lab Function (# of Systems)
Exhibit 94: Time Frame(s) for Sequencer Purchase Plan(s), by Industry/ Segment (% of Systems)
Exhibit 95: Time Frame(s) for Sequencer Purchase Plan(s), by Region (# of Systems)
Exhibit 96: Time Frame(s) for Sequencer Purchase Plan(s), by Region (% of Systems)
Exhibit 97: Sequencer Models Likely to Consider for Future Purchase
Exhibit 98: Sequencer Models Likely to Consider, by Brand/ Type Owned (# of Labs)
Exhibit 99: Sequencer Models Likely to Consider, by Brand/ Type Owned (% of Labs)
Exhibit 100: Sequencer Models Likely to Consider, Capillary/ Gel System-Only Owners
Exhibit 101: Sequencer Models Likely to Consider, Next-Generation System-Only Owners
Exhibit 102: Sequencer Models Likely to Consider, by Industry/ Segment (# of Labs)
Exhibit 103: Sequencer Models Likely to Consider, by Industry/ Segment (% of Labs)
Exhibit 104: Sequencer Models Likely to Consider, by Lab Function (# of Labs)
Exhibit 105: Sequencer Models Likely to Consider, by Lab Function (% of Labs)
Exhibit 106: Sequencer Models Likely to Consider, by Region (# of Labs)
Exhibit 107: Sequencer Models Likely to Consider, by Region (% of Labs)
Exhibit 108: Barriers or Issues Hindering 2nd and 3rd Generation Sequencers (# of Labs)
Exhibit 109: Barriers or Issues Hindering 2nd and 3rd Generation Sequencers (% of Labs)
